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Non-cytopathic (ncp) type 2 bovine viral diarrhea virus (BVDV-2) is widely prevalent in 
Argentina causing high mortality rates in cattle herds. In this study, we characterized 
an Argentinean ncp BVDV-2 field isolate (98-124) compared to a high-virulence refer-
ence strain (NY-93), using in  silico analysis, in  vitro assays, and in  vivo infections of 
colostrum-deprived calves (CDC) to compare pathogenic characters and virulence. In 
vitro infection of bovine peripheral blood mononuclear cells (PBMC) with BVDV 98-124 
induced necrosis shortly after infection while NY-93 strain increased the apoptotic rate 
in infected cells. Experimental infection of CDC (n = 4 each) with these strains caused 
an enteric syndrome. High pyrexia was detected in both groups. Viremia and shedding 
were more prolonged in the CDC infected with the NY-93 strain. In addition, NY-93 
infection elicited a severe lymphopenia that lasted for 14 days, whereas 98-124 strain 
reduced the leukocyte counts for 5 days. All infected animals had a diminished lymph-
oproliferation activity in response to a mitogen. Neutralizing and anti-NS3 antibodies 
were detected 3 weeks after infection in all infected calves. Virulence was associated 
with a more severe clinical score, prolonged immune-suppression, and a greater window 
for transmission. Studies of apoptosis/necrosis performed after in vitro PBMC infection 
also revealed differences between both strains that might be correlated to the in vivo 
pathogenesis. Our results identified 98-124 as a low-virulence strain.
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inTrODUcTiOn
Bovine viral diarrhea virus (BVDV) is a common pathogen of ruminants worldwide. Infections 
with BVDV lead to significant economic losses and have an important impact on the cattle industry 
(1–6). By infecting cells of the immune system, BVDV evokes an immunosuppression leading to 
a decreased immune response to other infectious agents (7). The immunosuppression elicited by 
BVDV includes a transient leukopenia in calves (8, 9), with diminished counts in peripheral B 
and T lymphocytes (10, 11), as well as monocytopenia and neutropenia (11, 12) with functional 
impairment of monocytes, dendritic cells, neutrophils, and lymphocytes (9, 11, 13, 14). BVDV 
also causes persistent infections (PI) by infecting the fetus in the early gestation period. Once 
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colostrum-derived immunity has declined, these PI animals 
continuously shed BVDV in large quantities (15, 16).
Bovine viral diarrhea virus is characterized by a strong genetic 
diversity and can be divided into two main species, BVDV-1 
and BVDV-2, each subdivided into sub-types (17). According 
to their effect on cell culture, two biotypes have been described, 
cytopathic (cp) and non-cytopathic (ncp), being ncp BVDV more 
frequent in nature. BVDV type-2 has been related with severe 
acute clinical signs and hemorrhagic disorders (18). In Argentina, 
ncp BVDV-2 strains have been associated with acute hemorrhagic 
enteritis in young cattle (19). BVDV-2 strains can be classified 
as high virulent or low virulent based on in vivo observations, 
such as pyrexia (i.e., T° >40°C for high virulent strains) and the 
time span of lymphopenia, among other signs (20). The charac-
terization of the virulence of different BVDV isolates was also 
determined by the clinical onset in newborn calves, as a model of 
infection (9, 12, 20–23). Many BVDV strains have been evaluated 
using colostrum-deprived calves (CDC) (20). This animal model 
is more suitable for reproducing the disease under controlled 
conditions, due to the lack of any maternal immune component 
that may interfere with virus infectivity.
Two nucleotide substitutions within the 5′ untranslated region 
(UTR) have been described, which differed between high- and 
low-virulence BVDV-2 isolates (24). These changes, positioned 
within the predicted IRES, may modulate the virus replication 
rate. However, later studies revealed that the correlation between 
sequence motifs and virulence are unclear and thus, other factors 
apart from sequence analysis should be considered (25).
In vitro studies have shown to be useful to study virulence of 
field strains. The reduction in the proliferation of lymphoma BL-3 
cells by in vitro infection with BVDV-2 strains has been applied as 
a qualitative measure of the lympho-cytopathogenicity induced 
by the virus (26). This fact can be used to estimate the percentage 
of apoptotic and necrotic circulating lymphoid cells after ex vivo 
BVDV-2 infection and as a parameter to define the degree of 
virulence of BVDV-2 strains.
The aim of this study was to characterize an Argentinean 
BVDV-2 ncp isolate, associated with mild enteritis and general 
dermatitis in the field. Virulence analysis of this strain was per-
formed in parallel with a previously characterized high virulent 
type 2 strain isolated in New York in 1993 “NY-93” (26, 27) using 
in silico and in vitro methods, supported by in vivo infection of 
CDC. We used virus grown in MDBK cells, as Meyer et al. (28) 
demonstrated that MDBK-grown NY-93 strain, even produced 
by a cDNA clone, was clinically indistinguishable from the wild-
type virus in animal experiments. We also evaluated if the clinical 
signs developed by the CDC in response to the experimental 
infection with BVDV 98-124 were similar to those described in 
the field. This study can be helpful to further assess therapeutic 
treatments and vaccines against BVD.
MaTerials anD MeThODs
Viruses
Non-cytopathic BVDV 98-124 strain (genotype 2b, GenBank 
accession number MH074881) was isolated from tissue samples 
of cattle that showed purulent nasal secretions, ptyalism, severe 
hemorrhagic watery diarrhea, and dehydration, during an out-
break in Buenos Aires province (Argentina) in 1998 (29). Details 
of the necropsy findings during this outbreak were reported 
elsewhere (19). The virus used in this study was obtained from 
peripheral blood mononuclear cells (PBMC) of an infected 
calf, processed for virus isolation (VI) by inoculating a 10% 
cell homogenate onto cultures of Madin–Darby Bovine kidney 
(MDBK) cells, as described below. Stock was prepared from a 
third passage in MDBK cells.
The BVDV-2 strain New York 93 (NY-93) was isolated in 
1993 from an outbreak that took place in New York following the 
importation of a heifer from Canada. The severe acute clinical 
presentation included hemorrhagic signs, elevated rectal tem-
peratures and death loss (30). The NY-93 BVDV-2 strain, kindly 
provided by Dr. R. Donis, was used as a “control reference” virus 
strain in this work.
animals
Newborn male Holstein calves were purchased from a dairy 
farm in Buenos Aires. They were removed from their mothers 
immediately after birth before they can consume colostrum. 
Calves (mean weight at birth 32.13 ±  2.03 kg) were housed in 
the biosecurity boxes (BSL2) located at the Research Center of 
Veterinary Sciences (CICVyA) INTA Castelar, Buenos Aires. They 
were negative for BVDV at birth, as determined by VI from WBC 
samples followed by detection based on reverse transcriptase 
polymerase chain reaction (RT-PCR) assay (31). They were also 
free for antibodies against BVDV at birth, as assessed by serum 
neutralization test using BVDV type-1 (NADL strain) and BVDV 
type-2 VS253 strains (29).
Upon arrival, calves were sanitized with 0.2% benzalkonium 
chloride and dried with a towel with vigorous movements to 
stimulate the peripheral circulation. The navel was disinfected 
with iodine alcohol (1:1 alcohol and iodine) twice a day until it 
was dry. An antibiotic-therapy schedule was applied: Ceftiofur 
Sodium (Ceftiomax, Biogenesis Bagó, Argentina) was admin-
istered intramuscularly on daily bases during the first 10 days 
of life (dose: 6 mg/kg of body weight) and Gentamicin sulfate 
was injected intravenously once a day during the first 5  days 
of life (Gentamicin, Equi Systems, Argentina; 8 mg/kg of body 
weight).
Calves were fed with a milk replacer (AF80, ACA, Argentina), 
free of immunological components and balanced food (18% 
protein content; Start calves, ACA, Argentina). The milk replacer 
was always administered warm (37–38°C) using a calf feeding 
bottle and getting the calf in a head up position to obtain a proper 
esophageal leak enclosure. They were periodically assessed for 
serum neutralizing antibodies (Nab) against BVDV type-1 and 
type-2, as described above. All animals received 1 ml of vitamin 
AD3E (500,000 UI Vitamin A, Vitamin D3 75,000 UI, Vitamin E 
50 mg; Bagó AD3E, Biogenesis, Argentina) parenterally.
Colostrum-deprived calve handling, inoculation, and sample 
collection were performed by trained personnel under the super-
vision of a veterinarian and following national animal welfare 
regulations (Protocol N° 02/2010 from CICUAE, INTA).
TaBle 1 | Clinical signs and designated score.
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sequence analysis of the 5′UTr region
Polymerase chain reaction and sequencing for 98-124 strain 
was performed as previously described (29). Sequences were 
trimmed and analyzed with Bioedit Software (32) to obtain a 
236 bp fragment, corresponding to the 5′UTR region of BVDV. 
A multiple sequence alignment of four low-virulence strains 
(17011, 7937, 713, and 5521; GenBank accession numbers 
AF039179, AF039175, AF039177, and AF039174, respectively), 
four high-virulence strains (890, NY-93, 17583, and 23025; 
GenBank accession numbers AF039180, AF039173, AF039176, 
and AF039172, respectively), Osloss reference strain (M96687) 
and 98-124 strain (MH074881) was performed with ClustalW, 
Version 1.8.3 (33). Analysis of virulence indicators considered 
nucleotide positions 219 and 278 of Osloss strain as described by 
Topliff and Kelling (24).
apoptosis–necrosis assessment
Peripheral blood mononuclear cell (1 × 106 per well) were infected 
with 98-124 isolate (multiplicity of infection “mock” = 1) or mock 
infected (cells incubated with a clarified MDBK lysate instead 
of viral inoculum) for 1  h at 37°C in duplicates, washed by 
centrifugation and cultured in complete RPMI (containing 10% 
BVDV-free FCS, already controlled for BVDV antigen, genome 
and antibodies; 1X Glutamine; 25 mM HEPES and 1X Antibiotic-
Antimycotic, all reagents are from GIBCOTM) in a 48-well plate 
at 37°C and 5.5% CO2. The cells were analyzed by flow cytometry 
using PE Annexin V Apoptosis Detection Kit (BD Biosciences 
Pharmingen, CA, USA) as described before (9). Annexin V and 
7-AAD negative are viable cells. Early apoptotic cells are Annexin 
V positive and 7-AAD negative while late apoptotic and necrotic 
cells are 7-AAD positive (34).
experimental infection
Eight animals were randomly assigned to two treatment groups 
(n = 4 animals each) and infected at 50 days of age (mean weight 
55.93 ± 2.15 kg) with 5 ml of a culture supernatant containing 
106 TCID50/ml of ncp BVDV 98-124 or ncp BVDV NY-93 strain. 
Virus inoculum was instilled into the nostrils. Infections with 
the two different strains were performed 4 months apart in order 
to prevent possible co-infections.
Monitoring of clinical signs and sampling
All inoculated calves were examined twice a day. Rectal tempera-
ture and clinical signs were recorded. Based on the observation 
of anorexia, sensorium, diarrhea, nasal and ocular discharge, 
and respiratory signs (dyspnea and cough) a clinical score was 
designed (Table 1). The recorded values for each 98-124 or NY-93 
infected CDC (n = 4 for each group) were plotted and computed 
as the area under the curve (AUC). Whole blood samples and 
nasal swabs (NSs) were collected 1 day before challenge and daily 
during the first 20  days post-infection (dpi). Blood cells were 
separated by and put through one freeze–thaw cycle for virus 
isolation. NSs were immediately submerged in 1 ml of DMEM 
cell culture medium and placed on ice. Blood samples were also 
collected in heparinized sample tubes for leukocyte counts and 
ARN extraction, these samples were processed in an automatic 
hematology analyzer Celldyn 3500-LASER (Abbott Laboratories, 
Abbott Park, Ill, USA).
Virus isolation
Thirty microliters of lysate [either white blood cells (WBC) or 
NS] were used to inoculate 4 wells of a 96-well plate with 70% of 
confluent MDBK cells. After rocking at 37°C for 1 h, the inocu-
lum was removed from the cells and replaced with 150 µl of cell 
culture media. After 3 days, the cell culture (including media) 
was frozen at −80°C. After thawing to room temperature, 30 µl of 
the resulting lysate was added to a fresh MDBK cells monolayer 
and rocking at 37°C for 1 h, after that the inoculum was replaced 
with 150 µl of cell culture media. After three passages in MDBK 
cells, detection of BVDV antigens was performed by IF (VMRD 
BVDV Direct FA Conjugate, WA, USA).
humoral immune response
A commercial kit was used to detect antibodies against BVDV 
NS3 following manufacturer’s instructions (PrioCHECK™ 
Bovine BVDV Ab Plate Kit, Thermo Fisher Scientific, USA). Nab 
titers in serum samples were tested by virus-neutralization against 
the homologous strain used for each experimental infection, as 
described previously (29).
Proliferation inhibition assay
Peripheral blood mononuclear cells from infected animals with 
BVDV 98-124 and NY-93 strains were stimulated with Concavalin 
A (ConA, Sigma, USA). Inhibition of PBMC proliferation was 
evaluated at 0, 5, 8, 10, and 18 dpi. Briefly, triplicates of PBMC 
cells were seeded in 96-well plates (300,000 cells/well) and incu-
bated with ConA (10 µg/ml) in 100 µl cell culture media for 72 h 
at 37°C in an atmosphere of 5% CO2. After the incubation, the 
proliferative response was determined by using the XTT assay 
following the manufacturer’s instructions (TACSTM XTT Cell 
proliferation/viability assay, R&D Systems, MN, USA). Results 
were expressed as the percentage of residual proliferation respect 
to values obtained at 0 dpi.
FigUre 1 | Type 2 bovine viral diarrhea virus 5′UTR sequence alignment. Squares show nucleotide differences at positions 219 and 278 between low- and 
high-virulence strains. Accession numbers: 23025: AF039172, NY-93: AF039173, 5521: AF039174, 7937: AF039175, 17583: AF039176, 713: AF039177,  
17011: AF039179, 890: AF039180; 98-124: MH074881.
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Quantitative real-Time Polimerase  
chain reaction (qrT-Pcr)
Virus RT-qPCR was performed using Pan Pestivirus primers 
324-326 (2) to amplify a 288 pb fragment of the 5′UTR region of 
BVDV. RNA was extracted from blood and frozen NS of infected 
animals and from infected PBMC and cell culture media of the 
apoptotic–necrotic assay using Trizol Reagent (Invitrogen, CA, 
USA). Reverse transcription was carried out using the antisense 
primer and Reverse Transcriptase (from Moloney murine 
leukemia virus [M-MLV]; Promega, USA) under standard 
conditions and 500 ηg of total ARN. The EVA Green® dye was 
used in this real-time RT-PCR method contained in the master 
mix (Mezcla Real; Biodynamics, Argentina) and ROX reference 
dye (Invitrogen, USA). The standard samples used were plasmid 
containing BVDV PCR products cloned into pGemT (Promega, 
WI, USA). Samples and standards were run in triplicate in an ABI 
7500 thermocycler (Applied Biosystems, CA, USA) and analyzed 
using model 7500 SDS software v 1.3.1.
statistics
Neutralizing antibody titers were logarithmically transformed 
(log10) to comply with homogeneity of variance and normal dis-
tribution. In those cases when the data met a normal distribution 
(Wilk–Shapiro normality test) and their variances were compara-
ble, Bartlett Test statistical analyzes were performed using one- or 
two-way ANOVA followed by Bonferroni multiple comparison 
test, using STATISTIX 7x software (Analytical Software, TN, 
USA). For comparing clinical AUC scores of two groups of data, 
the Mann–Whitney test was used. The analysis was performed 
with MedCalc version 12 (Medcalc bvba software used, CA, 
USA). In all cases, a confidence interval of 95% was considered.
resUlTs
analysis sequence Motifs in the  
5′UTr region
The sequences obtained by RT-PCR amplification and direct 
sequencing of NY-93 and 98-124 strains were trimmed and ana-
lyzed. The two-base substitution described for BVDV-2 strains 
(24) were mapped along the sequence comprised between posi-
tions 219 and 278 of the 5′UTR. The low-virulence strain (98-124) 
presented a Cytosine at position 219, while the high-virulence 
strain (NY-93) had an Uracil. On the contrary, at position 278, the 
high-virulence strain had a Cytosine whereas the low-virulence 
strain had an Uracil (Figure 1).
In Vitro studies
Peripheral blood mononuclear cells (PBMC) from BVDV-
negative calves were infected in  vitro with both type-2 strains 
(moi  =  1) and the viability of the infected cells was assessed 
by measuring apoptosis and necrosis using Annexin V/7-AAD 
staining. The basal rate of apoptotic and necrotic cells was 1.77 
and 1.22%, respectively. PBMC in  vitro infected with 98-124 
underwent cell death shortly after infection. The number of dead 
cells displayed a maximum rate of 91.9% at 7 dpi (Figures 2A,B). 
A shift from 7-AAD negative to positive staining in Annexin V 
positive cells (upper left to right area) was observed over time for 
PBMC infected with NY-93 strain. Apoptotic cells (Annexin V 
positive, 7-AAD negative) peaked at 5 dpi (34.15%) and decreased 
thereafter up to 29.89% at 7 dpi, while dead cells (both necrotic or 
late apoptotic) increase from 36.02% at 2 dpi to 60.3% at the end 
of the experiment (Figure 2C).
A maximum peak in viral RNA levels was detected at 5 dpi 
(8,400 copies per 100  ηg of total RNA) in peripheral blood 
mononuclear cells (PBMC) infected with BVDV 98-124. Values 
decreased thereafter to non-detectable levels at 7 dpi. Conversely, 
PBMC infected with NY-93 showed a sharp increase in the 
number of viral RNA copies at 2 dpi that peaked at 5 dpi, with 
values approximately 3.5 times higher than those observed with 
the other strain (p < 0.05; Figure 2D). Similar levels of RNA to 
those measured at 2  dpi we still observed at 7  dpi. At all-time 
points, RNA levels were higher in PBMC infected with NY-93 
compared to BVDV 98-124.
experimental infection of cDc
Groups of 4 CDC were infected, with 98-124 or NY-93 strain, 
at 50 days of age when immune parameters were comparable to 
those described for adult animals. Clinical signs and rectal tem-
perature were recorded twice a day and clinical score values were 
plotted and computed as the AUC. The assigned clinical score for 
each clinical sign was detailed in Table 1.
All challenged calves developed gastrointestinal signs after 
BVDV infection. Clinical signs were mild in the group infected 
FigUre 2 | Viability and virus load of ex vivo-infected peripheral blood mononuclear cells (PBMC). PBMC were infected with bovine viral diarrhea virus (BVDV) 
NY-93 or 98-124 strains and stained with Annexin V/7-AAD at 0, 2, 5, and 7 DPI. (a) Dot plot of a representative experiment showing apoptotic and necrotic cells  
at different days after infection. Line graphs depict the kinetics of apoptotic and necrotic PBMC infected with 98-124 (B) and NY-93 (c). (D) Viral RNA load in 
infected PBMC. Results are expressed as RNA viral copies/100 ng of total RNA. Results are mean values from three independent experiments. Horizontal line 
indicates the sensitivity limit of the qRT-PCR. DPI, days post infection. Lowercase letters above each bar indicate significant differences (p < 0.05).
5
Malacari et al. Characterization of BVDV Type II Strains
Frontiers in Veterinary Science | www.frontiersin.org April 2018 | Volume 5 | Article 75
with BVDV 98-124. Calves exhibited depressed sensorium asso-
ciated with pyrexia and anorexia. A biphasic pyrexia profile was 
found around 3 dpi and between 6 and 8 dpi (Figure 3A). A non-
aqueous mild diarrhea developed after infection that continued 
for 2 days. All animals showed a mild hematochezia during the 
first day of the diarrhea. The AUC for the group infected with 
98-124 was 10 ± 2.16, mainly due to the presence of diarrhea.
Calves infected with NY-93 developed anorexia and depressed 
sensorium from 4 to 18 dpi. They also underwent hemostatic dis-
orders evidenced by a decreased clotting time (data not shown) 
and hematochezia. Calves suffered from aqueous diarrhea and 
a marked dehydration (>5%, from 11 to 16  dpi) and received 
proper rehydration treatment. Only two animals infected with 
NY-93 strain presented biphasic pyrexia, with the first peak 
between 3 and 6  dpi and a maximum record of 39.9°C; while 
the other peak was observed between 7 and 18 dpi (42.1°C). The 
other two animals showed sustained pyrexia from 2 to 12  dpi 
and from 1 to 18 dpi. The maximum t° was 41.2°C (Figure 3A). 
The AUC for the NY-93 CDC infected was 37.75  ±  8.07. This 
value was significantly higher than that scored by BVDV 98-124 
(p < 0.05).
Animals infected with 98-124 strain developed leukopenia 
between 2 and 7  dpi with a minimum count of 2520  L/mm3, 
while leukopenia was recorded between 2 and 19 dpi in animals 
infected with NY-93 with a minimum count of 1280  L/mm3 
(Figure 3B). The average WBC reduction was about 68 and 78% 
for 98-124 and NY-93 strain infected group, respectively.
One animal infected with NY-93 strain died at 18 dpi, even 
though it received intra-venous fluids. It had interdigital hemor-
rhagic ulcerations in the right forelimb and in the ocular mem-
brane, and petechiae with widespread distribution in the lungs and 
pleura. Blood vessels were enlarged and the heart showed signs of 
endocarditis. The abdominal cavity and the gastrointestinal track 
also had the same pattern of lesions, with widespread petechial 
hemorrhages in several tissues, including the mucosa (Figure 4).
Viremia and shedding
Viral RNA was detected in blood from 1 to 12  dpi in calves 
infected with 98-124 strain, with a maximum number of viral 
RNA copies at 7 dpi (1.1 × 106 ± 3.2 × 105 copies/ml). Animals 
infected with NY-93 strain had positive viral RNA detection from 
2 to 18 dpi, with a maximum values measured from days 8 to 10 
post-infection (Figure 5, upper panel). Virus was isolated from 
WBC at 4 dpi in BVDV 98-124 infected calves, and viral detection 
was positive for about 10 days. Virus isolation results were posi-
tive for NY-93 infected animals from days 3 to 17 post-infection 
(Figure 5, lower panel).
Viral RNA was detected in NS samples from 3 to 9  dpi 
in all animals infected with 98-124 with a peak value of 
1.1 × 104 ± 5.4 × 103 copies/ml at 7 dpi. Animals infected with 
FigUre 4 | Necropsy of the animal infected with bovine viral diarrhea virus NY-93. The animal was found dead on day 18 post infection. (a) The yellow arrow 
indicates a disseminated bleeding in the base of the aorta and pulmonary arteries. The green arrow shows petechiae in the pericardium. (B) The white arrow  
depicts bleeding in the endocardium. Disseminated bleeding was found in esophagus (c), rumen (D), spleen (e), and reticulum (F).
FigUre 3 | Clinical signs in infected calves: temperature and lymphopenia. Kinetics of mean rectal temperatures (a) and white blood cells (WBC) counts  
(B) measured in colostrum-deprived calves infected with bovine viral diarrhea virus 98-124 or NY-93 strains at different days post-infection. The dotted line  
indicates the lower limit of WBC count to consider a clinical leukopenia and the gray square delimits the normal rectal temperature range for calves.
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NY-93 had positive shedding for 14 days (3–16 dpi) and the mean 
maximum viral RNA load was ~8 × 103 ± 3 × 103 copies/ml from 
8 to 11 dpi (Figure 5, upper panel). Virus was isolated from nasal 
secretions from 3 to 8 dpi in calves infected with 98-124 strain; 
and from 2 to 10  dpi in those infected with NY-93 (Figure  5, 
lower panel).
effect on adaptive immunity
Neutralizing antibodies against each homologous strain as well as 
antibodies against NS3 were assessed in serum samples obtained 
at 0 dpi and after infection, up to 20 dpi. In both experimental 
groups, neutralizing and anti-NS3 antibodies were first detected 
at 20 dpi (Figure 6A).
FigUre 5 | Viremia and shedding. Upper panel: bovine viral diarrhea virus (BVDV) RNA quantification (qRT-PCR) from blood or nasal swabs (NSs) samples  
of colostrum-deprived calves (CDC) infected with either BVDV strain at different times post infection. Results are expressed as viral RNA copy number per  
milliliter. (*) values significantly superior to those measured at 0 dpi (p < 0.05). Lower panel: viral isolation from white blood cells (WBC) and NSs of CDC  
infected with both BVDV strains.
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FigUre 6 | Humoral responses and impairment of cell-mediated immunity. (a) Humoral response of colostrum-deprived calves infected with bovine viral diarrhea 
virus 98-124 or NY-93 strains. Connecting lines correspond to antibodies against NS3 and neutralizing antibodies against each homologous strain are shown with 
bars. (B) Cellular immune response was tested by a proliferation assay performed using peripheral blood mononuclear cells (PBMC) from calves at different days 
post infection and compared to values obtained at 0 dpi. Lowercase letters and numbers above each bar indicate significant differences (p < 0.05) between time 
points for 98-124 or NY-93 infected PBMC, respectively. (*) Significant differences between groups are indicated (p < 0.05).
Peripheral blood mononuclear cells from all infected calves 
had a reduced capacity to proliferate in response to Concanavalin 
A (ConA) from 5 to 18 dpi. The maximum reduction in the pro-
liferation index in PBMC obtained from BVDV 98-124 infected 
CDC was observed at 8 and 10 dpi, compared to values measured 
at 0 dpi. The capacity of these cells to respond to ConA stimula-
tion was partially recovered at 18  dpi, with similar values to 
those found at 5 dpi (p < 0.05; Figure 6B). Proliferation capacity 
was reduced gradually over time, and the lowest proliferation 
rate was measured at 10 and 18 dpi (Figure 6B).
DiscUssiOn
We have characterized an Argentinean BVDV type 2 strain in 
terms of virulence and pathogenicity, using in silico, in vitro, and 
in vivo methods. The BVDV-2b 98-124 Argentinean isolate had 
in  silico, in  vitro, and in  vivo features to classify it as a typical 
low-virulence type 2 strain. The parallel evaluation of the highly 
virulent and well-characterized NY-93 reference strain reinforced 
our experimental approach.
In silico analysis involved the evaluation of previously 
described nucleotide virulence indicators (24). We found a 
correlation between the presence of an Uracil and a Cytosine 
residues in positions 219 and 278 of the 5′UTR, respectively; 
and the clinical presentation of the disease in the CDC. Based 
on these markers, BVDV 98-124 was classified as a low-virulence 
strain. Although sequence analysis is fast to perform and easy 
to analyze, some flows have been reported. Giangaspero and 
Harasawa (35) showed that the substitution described by Topliff 
and Kelling (24) was only observed in some strains of genotype 
2b-BVDV, and that two hyper-virulent strains isolated from 
sheep had cytosine and Uracil in positions corresponding to that 
of the low-virulence strains. The authors highlighted the need 
to considering evolutionary divergence between strains when 
searching for common features as indicators of virulence. Thus, 
more studies are needed to apply sequence analysis for charac-
terizing BVDV-2 strains. In fact, Tautz et al. (25) reported that 
there is no clear correlation between specific sequence motifs 
and virulence, and proposed to analyze virulence considering 
multiple factors.
By performing ex vivo infections of bovines PBMC, we verified 
that virus load was higher and lasted longer in PBMC infected 
with NY-93, compared to 98-124. We also studied apoptosis and 
necrosis rates in these infected cells. Lymphocyte apoptosis has 
been previously described after BVDV infection (12). Apoptosis 
and necrosis rates of lymphocytes and lymphoid cell lines have 
been associated with virulence of BVDV strains (7, 26). Here, 
we showed that in  vitro PBMC infection with both BVDV 
strains revealed a different rate of apoptosis and necrosis. BVDV 
98-124 induced a rapid increase in the number of necrotic cells; 
conversely, NY-93 induced an elevated apoptotic rate over time, 
with cells moving from being Annexin V positive and 7-AAD 
negative toward double positives over time. This pattern is usually 
observed for truly apoptotic cells.
The high virulent strain seems to be acting as a less acute 
“killer,” promoting a high apoptotic rate sustained over time. The 
interpretation on the role of apoptosis and necrosis of PBMC in 
the pathogenicity of several viruses including BVDV has changed 
over the last 10 years. Multiple forms of regulated necrosis have 
shown to have a key role in pathologies such as sepsis, inflamma-
tory diseases and infectious disorders (36). A burst of necrotic 
bodies shortly after infection may trigger a pro-inflammatory 
response that can promote, anti-viral responses and secretion of 
TNF-α among other pro-inflammatory cytokines. The pattern of 
apoptosis/necrosis induction may be regulated by TNF-α while 
the production of TNF-α can be associated with BVDV virulence 
(37). Further experiments are needed to clarify the relationship 
between TNF-α and BVDV-2 virulence and the possibility of 
assessing virulence by measuring apoptosis rates of in  vitro 
infected PBMC.
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Leukopenia is a clinical sign associated with the infection 
of cattle with different strains of BVDV (11, 37). Experimental 
infection of CDC with both the high and low virulence provoked 
a reduction in WBC counts greater than 60% for both strains; 
however, leukopenia differed in the duration, suggesting that 
NY-93 would expose infected animals to acquire secondary infec-
tions for longer periods than the low-virulence strain. Another 
interesting observation is the comparable level of reduction in 
WBC counts, suggesting that this value by itself may not be a 
feature strictly related to the virulence of the infecting strain. 
Thus, it is important to consider other clinical signs such as rectal 
temperature and clinical signs, as discussed below.
We observed biphasic pyrexia as the infection proceeded. 
This pattern has already been reported in CDC (12, 23, 38). The 
severity of pyrexia after infection has been associated with the 
virulence of the strain, which is concordant with our results.
Both groups developed a gastrointestinal syndrome with 
watery diarrhea and depression after infection, with differences in 
the severity and duration of the symptoms. Calves infected with 
BVDV 98-124 suffered a mild non-watery diarrhea that lasted 
for one or two consecutive days, while those infected with NY-93 
developed a severe gastrointestinal syndrome with watery diar-
rhea and depression for several consecutive days. One of the four 
NY-93-infected calves died at 18 dpi, caused by the hemostatic 
disorder. This type of hemorrhagic syndrome has been previously 
described in experimental infections with this particular strain 
and with other BVDV-2 strains (27, 39).
The severity of clinical signs can be related to the level of 
viremia (40). Calves infected with BVDV 98-124 or NY-93 
showed differences in the time-span of viremia (circulating virus) 
and shedding (virus in NSs), while peak amounts of BVDV RNA 
in both blood and NSs were comparable. In concordance with 
previous observations, in our experimental conditions and based 
on the significantly longer period of viral excretion detected, 
the high-virulence NY-93 strain would be more effective in the 
transmission by aerosol or nasal contact than 98-124.
Another effect of BVDV on the immune system is the interfer-
ence with cell-mediated immunity in vivo. Here, we showed that 
infection of CDC with both strains impaired lymphoprolifera-
tion in response to a mitogen along all the observation period. 
Interestingly, the lymphoproliferation capacity was only partially 
recovered at 18 dpi only in 98-124 infected calves. These results 
evidenced the immune suppression triggered by BVDV infec-
tion that accounts for the susceptibility usually observed against 
opportunistic pathogens. These results also show that this effect 
seems to be sustained in time for the highly virulent strains.
The presence of Nab in animals infected with BVDV has been 
usually detected approximately 3 weeks after challenge (41). In this 
study, CDC infected with both strains developed antibodies 
against NS3 and low titers of Nab at 20 dpi, consequent with the 
immunosuppression caused by these ncp BVDV strains.
We have classified the Argentinean field isolate BVDV 98-124 
as a low virulent strain by assessing different parameters both 
in vitro and in vivo. The use of a well-characterized strain was a 
valuable tool to validate our results, supported by the fact that the 
strain produced on MBDK cells is relevant for an in vivo study 
(28). In silico, in vitro and in vivo assessments were concordant 
in identifying high and low-virulence strains. In vitro studies 
involving PBMC infection followed by assessment of apoptosis 
and necrosis rates may be explored as possible indicators of 
BVDV-2 virulence.
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